Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics LSD Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Lysosomal Storage Disorders (LSD) Prior Authorization Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage criteria for enzyme-replacement therapies used to treat lysosomal storage disorders for Boeing commercial members, including requirements for initial and continuation therapy and non-preferred agents.

    Policy Summary
    PayerPrime Therapeutics
    PolicyLysosomal Storage Disorders (LSD) Prior Authorization Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionBefore requesting a non-preferred agent, document preferred-agent failure, intolerance, or contraindication and obtain the required physician attestation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    11Prior authorization agents
    2Non-preferred drugs
    All membersContinuation eligibility
    5 months+Youngest explicit minimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5 years+
    Minimum age for Vimizim and Elaprase

    Coverage Criteria

    Continuation Therapy for Non-Preferred Agents

    Continuation of therapy with non-preferred agents is considered medically necessary for all members, including new members, when ALL of the following are met:

    ALL of the following

    • The individual is currently receiving the requested medication for an indication listed below.
    • The individual is experiencing benefit from therapy, as evidenced by disease stability or disease improvement.
    • Dosing is in accordance with an authoritative source.

    Initial Therapy for Non-Preferred Agents

    Coverage for non-preferred agents will be provided when the applicable pathway below is met before use of the non-preferred agent:

    ONE of the following

    • ALL of the following

      • The individual has tried and failed, is intolerant to, or has a clinical contraindication to the preferred agent.
      • The physician attests that, in their clinical opinion, the same intolerance, contraindication, lack of clinical efficacy, or adverse event would not be expected to occur with the non-preferred agent.
    • The preferred drugs are experiencing documented drug shortages or recalls from a wholesaler, manufacturer, the ASHP (American Hospital of Health-System Pharmacist) Drug Shortage web page, or the U.S. Food and Drug Administration.
    • Cerezyme is requested for a member older than 2 years and younger than 4 years.

    Product-Specific Medical-Necessity Indications

    Enzyme-replacement therapy used for the treatment of lysosomal storage disorders may be considered medically necessary for the specific product and indication criteria below.

    ONE of the following product-specific criteria

    • Agalsidase beta (Fabrazyme®)

      • The individual is 2 years of age or older.
      • The individual has a confirmed diagnosis of Fabry disease.
    • Avalglucosidase alfa-NGPT (Nexviazyme®)

      • The individual is 1 year of age or older.
      • The individual has a diagnosis of late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).

    Provider Actions

    Prior Authorization

    Prior Authorization Required for LSD Enzyme Replacement

    Prior authorization is required for lysosomal storage disorder enzyme-replacement therapy. The program applies to the following products and specified generic agents:

    • Vimizim — elosulfase alfa solution for IV infusion, 5 mg/5 mL (1 mg/mL)
    • Naglazyme — galsulfase solution for IV infusion, 1 mg/mL
    • Elaprase — idursulfase solution for IV infusion, 6 mg/3 mL (2 mg/mL)
    • Cerezyme — imiglucerase for injection, 400 units
    • Aldurazyme — laronidase solution for IV infusion, 2.9 mg/5 mL (500 units/5 mL)
    • Kanuma — sebelipase alfa IV solution, 20 mg/10 mL (2 mg/mL)
    • Elelyso — taliglucerase alfa for injection, 200 units
    • Vpriv — velaglucerase alfa for injection, 400 units
    • Mepsevii — vestronidase alfa-vjbk IV solution, 10 mg/5 mL
    • Fabrazyme — agalsidase beta for IV solution, 5 mg and 35 mg
    • Lumizyme — alglucosidase alfa for IV use, 50 mg

    Background

    Lysosomal storage disorders are inherited conditions involving deficient lysosomal enzymes or related lysosomal function. Enzyme-replacement therapy replaces or supplements the deficient enzyme and is used for disease-specific disorders such as Fabry disease, Pompe disease, Gaucher disease, mucopolysaccharidoses, Hunter syndrome, and lysosomal acid lipase deficiency. Coverage is based on the requested product, diagnosis, age, and applicable authorization requirements.

    Definitions

    Enzyme-replacement therapy
    DefinitionTherapy used to replace or supplement a deficient lysosomal enzyme.
    PurposeUsed to treat lysosomal storage disorders.
    Policy contextCoverage may be considered medically necessary when used for a specific product and disease indication listed in the policy.
    Fabry disease
    DefinitionA lysosomal storage disorder associated with alpha-galactosidase A deficiency.
    Covered therapyFabrazyme may be considered medically necessary for individuals with a confirmed diagnosis of Fabry disease.
    Minimum age for Fabrazyme

    Initial Therapy Criteria

    Initial Therapy for Non-Preferred Agents

    Coverage for a non-preferred agent is contingent on meeting one of the following applicable initial-therapy pathways.

    Initial non-preferred therapy pathways

    • Preferred-agent failure, intolerance, or contraindication

      • The individual has tried and failed, is intolerant to, or has a clinical contraindication to the preferred agent.
      • The physician attests that the same intolerance, contraindication, lack of clinical efficacy, or adverse event would not be expected to occur with the requested non-preferred agent.
    • Shortage or recall pathway: The preferred drug is experiencing a documented shortage or recall from a wholesaler, manufacturer, the ASHP Drug Shortage webpage, or the U.S. Food and Drug Administration.

    Continuation Criteria

    Non-Preferred Continuation Therapy

    Continuation of therapy with non-preferred agents is considered medically necessary for all members, including new members, when all of the following are met.

    Continuation requirements

    • The member is currently receiving the requested medication for an indication listed in the policy.
    • The member is experiencing benefit from therapy, evidenced by disease stability or disease improvement.
    • Dosing is in accordance with an authoritative source.

    Step Therapy

    Step-therapy elementRequirement
    Non-preferred agentsCerezyme and Elelyso are identified as non-preferred drugs.
    Preferred-agent exceptionBefore initiating a non-preferred agent, the individual must have tried and failed, been intolerant to, or had a clinical contraindication to the preferred agent.
    Physician attestationThe physician must attest that the same intolerance, contraindication, lack of clinical efficacy, or adverse event would not be expected with the requested non-preferred agent.
    Shortage or recall exceptionThe preferred drug has a documented shortage or recall from a wholesaler, manufacturer, the ASHP Drug Shortage webpage, or the U.S. Food and Drug Administration.
    Cerezyme age exceptionCerezyme may be requested for a member older than 2 years and younger than 4 years; this is an exception to the preferred-agent requirement and physician attestation.
    Policy Summary
    PayerPrime Therapeutics
    PolicyLysosomal Storage Disorders (LSD) Prior Authorization Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionBefore requesting a non-preferred agent, document preferred-agent failure, intolerance, or contraindication and obtain the required physician attestation.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy
  1. Idursulfase (Elaprase™)

    • The individual is 5 years of age or older.
    • The individual has a diagnosis of Hunter syndrome (mucopolysaccharidosis II [MPS II]).
  2. Alglucosidase alfa (Lumizyme®, formerly known as Myozyme®) is requested for an individual with Pompe disease (GAA deficiency).
  3. Asfotase alfa (Strensiq®) is requested for treatment of an individual with perinatal/infantile-onset or juvenile-onset hypophosphatasia.
  4. Elosulfase alfa (Vimizim®)

    • The individual is 5 years of age or older.
    • The individual has mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
  5. Galsulfase (Naglazyme®) is requested for an individual with mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome).
  6. Imiglucerase (Cerezyme®)

    • The individual is 2 years of age or older.
    • The individual has a diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions: bone disease; hepatomegaly or splenomegaly; or thrombocytopenia.
  7. Laronidase (Aldurazyme®)

    • The individual is 6 months of age or older.
    • The individual has ONE of the following diagnoses

      • Hurler or Hurler-Scheie form of mucopolysaccharidosis I (MPS I).
      • Scheie form of MPS I with moderate to severe symptoms.
  8. Sebelipase alfa (Kanuma®)

    • The individual is 1 month of age or older.
    • The individual has lysosomal acid lipase deficiency.
  9. Taliglucerase alfa (Elelyso™)

    • The individual is 4 years of age or older.
    • The individual has a confirmed diagnosis of Type 1 Gaucher disease.
  10. Velaglucerase alfa (VPRIV®)

    • The individual is 4 years of age or older.
    • The individual has Type 1 Gaucher disease.
  11. Vestronidase alfa-vjbk (Mepsevii®)

    • The individual is 5 months of age or older.
    • The individual has mucopolysaccharidosis VII (MPS VII; Sly syndrome).
  12. Step Therapy

    Preferred-Agent Prerequisite

    For initial requests for a non-preferred agent, the individual must have tried and failed the preferred agent, be intolerant to it, or have a clinical contraindication to it.

    • The preferred-agent prerequisite applies before use of a non-preferred agent.
    • The request must document the applicable trial and failure, intolerance, or clinical contraindication.
    Documentation Required

    Physician Attestation Required

    For an initial non-preferred-agent request, the physician must attest that, in their clinical opinion, the same intolerance, contraindication, lack of clinical efficacy, or adverse event would not be expected to occur with the requested non-preferred agent.

    • Include the physician attestation with the initial request.
    • The attestation must address the documented preferred-agent issue and expected response to the non-preferred agent.
    Documentation Required

    Document Preferred-Drug Shortage or Recall

    The preferred-drug shortage or recall pathway requires documentation that the preferred drug is experiencing a shortage or recall.

    • Acceptable documentation may come from a wholesaler, manufacturer, the ASHP Drug Shortage website, or the U.S. Food and Drug Administration.
    • Document the affected preferred drug and the applicable shortage or recall.
    Documentation Required

    Continuation Response Documentation

    Continuation of therapy with a non-preferred agent may be medically necessary for all members, including new members, when the member is currently receiving the requested medication for a covered indication and is experiencing benefit from therapy.

    • Document current use of the requested medication for an indication listed in the policy.
    • Document clinical benefit through disease stability or disease improvement.
    • Confirm that dosing is consistent with an authoritative source.
    Denial Risk

    Failure to Meet Non-Preferred-Agent Criteria

    A non-preferred-agent request may be denied when the required initial or continuation criteria are not met.

    • Initial therapy: deny when there is no documented preferred-agent trial and failure, intolerance, or clinical contraindication, and no applicable documented shortage, recall, or Cerezyme age exception.
    • Initial therapy: deny when the required physician attestation is missing or does not support use of the non-preferred agent.
    • Continuation therapy: deny when current therapy, clinical benefit through disease stability or improvement, or authoritative-source dosing is not documented.
    Denial Risk

    Indication or Age Requirements

    Coverage may be denied when the requested enzyme-replacement therapy does not meet the policy's disease-specific indication or age requirement.

    • Fabrazyme: individual must be 2 years of age or older with confirmed Fabry disease.
    • Nexviazyme: individual must be 1 year of age or older with late-onset Pompe disease due to lysosomal acid alpha-glucosidase deficiency.
    • Elaprase: individual must be 5 years of age or older with Hunter syndrome (MPS II).
    • Lumizyme: individual must have Pompe disease (GAA deficiency).
    • Vimizim: individual must be 5 years of age or older with MPS IVA (Morquio A syndrome).
    • Naglazyme: individual must have MPS VI (Maroteaux-Lamy syndrome).
    • Cerezyme: individual must meet the applicable age requirement and have Type 1 Gaucher disease with bone disease, hepatomegaly or splenomegaly, or thrombocytopenia; a separate MPS I indication applies to individuals 6 months of age or older meeting the listed disease criteria.
    • Kanuma: individual must be 1 month of age or older and meet the applicable lysosomal acid lipase deficiency criteria.
    • Elelyso and Vpriv: individual must be 4 years of age or older with Type 1 Gaucher disease.
    • Mepsevii: individual must be 5 months of age or older with MPS VII (Sly syndrome).
    • Aldurazyme and Asfotase alfa requests must also meet the policy's applicable MPS I or perinatal/infantile- or juvenile-onset hypophosphatasia criteria.
    2 years of age or older.
    Pompe disease
    DefinitionA lysosomal storage disorder associated with lysosomal acid alpha-glucosidase (GAA) deficiency.
    Nexviazyme indicationLate-onset Pompe disease in individuals 1 year of age and older.
    Lumizyme indicationPompe disease due to lysosomal acid alpha-glucosidase deficiency.
    Cerezyme age exception: Cerezyme is requested for a member older than 2 years and younger than 4 years.>2 years and <4 years